Extracorporeal Membrane Oxygenation Cannula Market: as Getinge exits surgical perfusion to reallocate resources toward higher-growth ECMO and Medtronic launches its VitalFlow system across the US and Europe, capital and competitive attention is consolidating into the ECMO category specifically, so cannula demand tracks not only the underlying WHO-documented burden of cardiovascular disease and COPD but also which vendors are actively investing in easier-to-use, more configurable ECMO platforms that expand the pool of ICU teams capable of operating extracorporeal life support.

The global ECMO cannula market size was USD 786.4 Million in 2025 and is expected to register a revenue CAGR of 8.2% during the forecast period. Market revenue growth is driven by factors such as Getinge’s strategic exit from surgical perfusion to reallocate resources toward higher-growth ECMO and transplant care, Medtronic’s VitalFlow ECMO system launch expanding platform options across the United States and Europe, and the sustained global burden of cardiovascular disease and chronic obstructive pulmonary disease driving critical care demand for extracorporeal life support. The first driving factor is Getinge’s decision to phase out its surgical perfusion business and reallocate the freed resources toward extracorporeal life support, or ECMO, and transplant care, two categories the company has identified as higher-growth priorities. Getinge announced in January 2025 that it would phase out its cardiopulmonary surgical perfusion product portfolio, including its HL 40 heart-lung machine, by the end of 2025, explicitly to reallocate resources and management attention toward its ECMO and intra-aortic balloon pump offerings. The second driving factor is Medtronic’s launch of its VitalFlow ECMO system, a configurable, one-system solution that expanded from initial United States launch to European commercial availability following CE Mark approval. Medtronic received CE Mark approval for VitalFlow in June 2025 and formally launched the system in Europe in October 2025 at the European Association for Cardio-Thoracic Surgery annual meeting, expanding the commercially available ECMO platform options for European cardiac surgery and critical care teams. The third driving factor is the sustained global burden of cardiovascular disease and chronic obstructive pulmonary disease, which the World Health Organization documents as causing 19.8 million annual deaths and affecting 380 million people globally respectively, sustaining structural demand for both veno-arterial and veno-venous ECMO cannula systems. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a configurable, easier-to-use ECMO platform widens its own addressable market as it enables ICU teams without dedicated extracorporeal life support specialists to operate the system, letting one platform capture procedure volume from hospitals that previously lacked the specialist staffing to offer ECMO therapy at all. Once an ECMO platform is specifically engineered so that ICU team members regardless of specialised extracorporeal life support experience can operate it, that platform becomes viable for hospitals that previously could not offer ECMO therapy due to specialist staffing constraints, so platform usability improvement and total addressable hospital market expansion are directly linked rather than simply a customer experience refinement. As a result, demand and revenue share are concentrating around ECMO platform vendors investing specifically in usability and configurability, and the forecast tilts toward platforms designed for broader ICU team accessibility rather than systems requiring dedicated extracorporeal life support specialist staffing. For instance, Medtronic designed its VitalFlow system specifically so that every ICU team member, regardless of experience level, can operate it, incorporating feedback gathered from hundreds of clinicians with diverse ECMO specialties to address the most pressing unmet needs of simplicity, configurability, and performance, directly expanding the pool of hospitals capable of offering ECMO therapy beyond those with dedicated specialist staff. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is Getinge’s decision to phase out its surgical perfusion product line specifically to reallocate management attention and capital toward ECMO and transplant care. A major vendor redirecting capital and R&D investment away from a struggling adjacent category toward ECMO specifically signals genuine confidence in ECMO’s growth trajectory relative to alternatives, and this reallocation directly increases the pace of ECMO-specific product investment across the industry, so Getinge’s strategic pivot and accelerating ECMO platform investment are directly linked. Getinge announced in January 2025 that it would phase out its cardiopulmonary surgical perfusion product portfolio, including its HL 40 heart-lung machine and HCU 40 heater-cooler unit, by the end of 2025, with CEO Mattias Vadsten citing a decade of steadily decreasing market share and eroding margins in surgical perfusion as the rationale for reallocating toward ECMO. The recent record shows the pace. Industry analysts have identified LivaNova as a likely beneficiary of Getinge’s surgical perfusion exit, expecting the company to gain additional heart-lung machine market share as Getinge withdraws, illustrating how one vendor’s strategic reallocation reshapes competitive dynamics across the broader extracorporeal life support category. The effect on the market is that vendor strategic reallocation toward ECMO is accelerating the pace of platform innovation and competitive investment in the category beyond what underlying clinical demand growth alone would generate. These are some of the key factors driving revenue growth of the market.

The second driver is Medtronic’s VitalFlow ECMO system, specifically designed to be operable by ICU staff without dedicated extracorporeal life support specialist experience. ECMO programme establishment has historically required dedicated perfusionist or extracorporeal life support specialist staffing, and a platform engineered for broader ICU team usability directly removes that staffing constraint as a barrier to programme establishment, so platform usability design and total addressable hospital market expansion are directly and structurally linked. Medtronic received CE Mark approval for VitalFlow in June 2025 and formally launched the system in Europe in October 2025 at the European Association for Cardio-Thoracic Surgery annual meeting in Copenhagen, following the system’s initial United States launch in September 2024, expanding commercially available ECMO platform options across both major markets. The effect on the market is that VitalFlow and similarly usability-focused platforms are expanding the addressable hospital market for ECMO programme establishment beyond institutions with pre-existing dedicated specialist staffing. These are some of the key factors driving revenue growth of the market.

“Medtronic designed its VitalFlow ECMO system specifically so that every ICU team member, regardless of specialised extracorporeal life support experience, can operate it, directly expanding the pool of hospitals capable of establishing an ECMO programme beyond those with dedicated specialist staffing.”

The third driver is the sustained scale of global cardiovascular disease and chronic obstructive pulmonary disease burden, which underpins structural demand for both major ECMO configuration categories. Veno-arterial ECMO supports cardiac failure while veno-venous ECMO supports respiratory failure, and the scale of cardiovascular disease and COPD burden respectively sustains demand for each configuration category independently, so the two disease burden statistics map directly onto the two primary ECMO cannula type categories. The World Health Organization documents cardiovascular disease as causing 19.8 million annual deaths globally and COPD as affecting 380 million people globally, establishing the scale of the underlying critical care demand base that specialist cardiac and respiratory failure centres draw on for ECMO cannulation decisions. The effect on the market is that ECMO cannula demand growth tracks the combined scale of cardiovascular and respiratory disease burden directly, providing a demand floor for the market independent of any single vendor’s product strategy. These are some of the key factors driving revenue growth of the market.

However, the ECMO cannula market faces adoption constraints from the significant capital cost and specialist staffing requirements of establishing an ECMO programme, regulatory and quality compliance issues affecting some established vendors in adjacent extracorporeal life support categories, and anatomical and clinical suitability limitations inherent to ECMO cannulation. Because establishing an ECMO programme requires not only cannula and console capital investment but also dedicated perfusionist or extracorporeal life support specialist staffing, ongoing competency training, and 24-hour clinical coverage capability, smaller hospitals without a critical mass of cardiac or respiratory failure procedure volume often cannot justify establishing an in-house programme even where a more accessible platform design has lowered the operational skill barrier somewhat. Regulatory and quality compliance issues are a second constraint, since manufacturing quality concerns at some established extracorporeal life support product lines, addressed through FDA consent decrees and provider guidance urging transition away from specific affected products, have created market disruption and prompted more cautious purchasing behaviour that extends beyond the specifically affected vendor and products, reflecting the category’s overall sensitivity to demonstrated manufacturing quality given the life-critical nature of ECMO support. Anatomical and clinical suitability limitations are the third constraint, since ECMO cannulation carries meaningful vascular access complication and bleeding risk that limits appropriate use to patients where the expected clinical benefit clearly outweighs these risks, and this clinical risk-benefit threshold caps the addressable patient population for ECMO therapy below the full scale of underlying cardiovascular and respiratory disease burden documented by the WHO. These factors substantially limit ECMO cannula market growth over the forecast period.

Based on type, the global ECMO cannula market is segmented into veno-venous (VV) and veno-arterial (VA) ECMO cannula. Veno-arterial ECMO cannula hold the largest revenue share, because cardiac failure support applications, including post-cardiotomy shock and severe cardiogenic shock, represent the most established and highest-volume ECMO use case at specialist cardiac centres, which suits the WHO-documented scale of global cardiovascular disease burden. Veno-venous ECMO cannula are expected to register the fastest revenue growth rate in the global ECMO cannula market over the forecast period, driven by expanding respiratory failure support applications and rising severe COPD and acute respiratory distress syndrome case volumes, which is why respiratory failure-focused ICU centres represent a growing addressable market segment.

Based on patient type, the global ECMO cannula market is segmented into adult and pediatric/neonatal ECMO cannula. Adult ECMO cannula hold the largest revenue share, reflecting the substantially larger adult cardiovascular disease and COPD patient population relative to pediatric and neonatal ECMO indications, which suits the WHO disease burden data underpinning the broader market. Pediatric/neonatal ECMO cannula remain an established, specialised segment concentrated at dedicated pediatric cardiac and respiratory failure centres, generating steady demand tied to congenital cardiac and severe neonatal respiratory conditions requiring extracorporeal support.

Cardiac failure support application is expected to account for the largest revenue share in the global ECMO cannula market during the forecast period

Based on application, the global ECMO cannula market is segmented into respiratory failure support and cardiac failure support applications. Cardiac failure support holds the largest revenue share, reflecting the established position of veno-arterial ECMO in supporting patients with severe cardiogenic shock and post-cardiotomy failure at specialist cardiac centres. Respiratory failure support is expected to register rapid revenue growth in the global ECMO cannula market over the forecast period, driven by expanding veno-venous ECMO use for severe respiratory failure cases, which is why respiratory failure-focused ICU centres are increasingly investing in ECMO programme capability.

Based on regional analysis, the ECMO cannula market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the largest concentration of specialist cardiac and respiratory failure centres with established ECMO programmes, and because Medtronic launched its VitalFlow system in the United States first in September 2024, ahead of the subsequent European launch. The scale of cardiovascular disease and COPD burden in the United States, combined with the country’s concentration of academic medical centres capable of supporting dedicated ECMO specialist staffing, sustains the market’s leading position. The concentration of ECMO platform innovation and specialist centre infrastructure in the United States also means new ECMO cannula and console technologies are typically launched in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national ECMO cannula markets within Europe. Getinge, headquartered in the region, maintains a strong European installed base even as it reallocates resources from surgical perfusion toward ECMO, and Medtronic’s October 2025 European VitalFlow launch is expanding platform options regionally. The result is steady rather than rapid growth, shaped by the region’s already-established specialist cardiac centre infrastructure alongside active new-platform introduction.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, China, and South Korea represent the three largest national ECMO cannula markets within the region. Expanding critical care infrastructure investment and rising cardiovascular disease prevalence in China are driving new ECMO programme establishment from a comparatively lower installed base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national ECMO cannula markets within the region. Specialist cardiac centres in both countries are gradually expanding ECMO programme capability, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised cannula and console systems that Latin American cardiac centres depend on through 2026, slowing adoption beyond the region’s main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial ECMO cannula markets within the GCC. The UAE is the most established ECMO cannula market on the continent given its concentrated private cardiac centre infrastructure, while the wider Gulf states and broader African markets are still building specialist ECMO programme capability from scratch.